Virus-specific T cells from cryopreserved blood during an emergent virus outbreak for a potential off-the-shelf therapy.
暂无分享,去创建一个
S. Querol | F. Rudilla | Elena Valdivia | R. Mora-Buch | E. Enrich | L. Martorell | M. Piron | Gemma Aran | Maria Tomás-Marín | Mireia Antón-Iborra | Ana Gabriela Lara-de-León | Rut Mora-Buch
[1] M. Kamboj,et al. SARS-CoV-2 in immunocompromised individuals , 2022, Immunity.
[2] Peter Shaw,et al. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant , 2022, Blood advances.
[3] Christopher A. Lazarski,et al. Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products , 2022, Molecular Therapy - Methods & Clinical Development.
[4] M. Hallek,et al. Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy , 2022, Frontiers in Bioengineering and Biotechnology.
[5] J. Knight,et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study , 2022, The Lancet Microbe.
[6] Katherine K. Matthews,et al. SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants , 2022, PLoS pathogens.
[7] Oliver J. Klein,et al. Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients , 2022, Molecular Therapy - Methods & Clinical Development.
[8] D. Jekarl,et al. Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment , 2021, Frontiers in Immunology.
[9] Simona Baghai Sain,et al. Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection , 2021, Nature.
[10] Hongzhou Lu,et al. Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals , 2021, Cell discovery.
[11] A. Sette,et al. Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. , 2021, Blood advances.
[12] C. Farnsworth,et al. HLA genetic polymorphism in patients with Coronavirus Disease 2019 in Midwestern United States , 2021, HLA.
[13] P. Barie,et al. Virus Induced Lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics , 2021, Scientific Reports.
[14] Tamara J Laskowski,et al. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy , 2021, Cell Reports.
[15] E. Shin,et al. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells , 2021, Nature Communications.
[16] Gavin J. D. Smith,et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.
[17] L. Jarvis,et al. Rapid GMP-Compliant Expansion of SARS-CoV-2–Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19 , 2021, Frontiers in Immunology.
[18] M. Turner,et al. Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV‐specific T cell therapy , 2021, Clinical and experimental immunology.
[19] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[20] T. Mora,et al. Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection , 2021, eLife.
[21] S. Mallal,et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.
[22] J. Sibilia,et al. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France , 2020, Emerging infectious diseases.
[23] Christopher A. Lazarski,et al. SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein , 2020, Blood.
[24] P. Klenerman,et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses , 2020, Nature Communications.
[25] J. Greenbaum,et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.
[26] J. Deelen,et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19 , 2020, Journal of translational medicine.
[27] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[28] A. Sette,et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.
[29] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[30] M. J. Herrero,et al. HLA‐A, ‐B, ‐C, ‐DRB1, and ‐DQB1 allele and haplotype frequencies: An analysis of umbilical cord blood units at the Barcelona Cord Blood Bank , 2019, HLA.
[31] R. Krance,et al. "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. , 2019, Blood advances.
[32] A. Doglio,et al. A comparison of two protocols for optimal red blood cell depletion using Sepax-2 device for ABO-major incompatible transplantation in adults. , 2019, Current research in translational medicine.
[33] D. Bloom,et al. Infectious Disease Threats in the Twenty-First Century: Strengthening the Global Response , 2019, Front. Immunol..
[34] C. Bollard,et al. Virus-Specific T Cells for the Immunocompromised Patient , 2017, Front. Immunol..
[35] Mikhail Shugay,et al. Antigen receptor repertoire profiling from RNA-seq data , 2017, Nature Biotechnology.
[36] P. Hanley,et al. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy , 2016, Scientific Reports.
[37] Mikhail Shugay,et al. MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.
[38] M. Schilham,et al. Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection , 2010, Haematologica.
[39] M. Quigley,et al. CD4 T Cells Are Required for CD8 T Cell Survival during Both Primary and Memory Recall Responses1 , 2007, The Journal of Immunology.
[40] Urs Christen,et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.
[41] S. Mackinnon,et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.